Christopher Thomas Giordano

CIK: 0001871714

Transaction Breakdown

Open Market Buys (P)5 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (20.0%)

Derivative conversions

Awards (A)3 (30.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TENX

TENAX THERAPEUTICS, INC.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

TENX
TENAX THERAPEUTICS, INC.
Sep 15, 2026
Purchase(P)
Direct
4.9K shares at avg. $1.82$9K
TENX
TENAX THERAPEUTICS, INC.
Sep 11, 2026
Purchase(P)
Direct
6K shares at avg. $1.88$11K
TENX
TENAX THERAPEUTICS, INC.
Jul 13, 2026
Exercise(M)
Direct
219 shares at avg. $3.55$777.231
TENX
TENAX THERAPEUTICS, INC.
Jul 13, 2026
Exercise(M)
Direct
8.5K shares at avg. $5.94$50K
TENX
TENAX THERAPEUTICS, INC.
Jan 9, 2026
Award(A)
Stock Option (right to buy)
Direct
450K shares-
TENX
TENAX THERAPEUTICS, INC.
Nov 20, 2025
Purchase(P)
Direct
538 shares at avg. $7.59$4K
TENX
TENAX THERAPEUTICS, INC.
Nov 19, 2025
Purchase(P)
Direct
455 shares at avg. $7.51$3K
TENX
TENAX THERAPEUTICS, INC.
Nov 18, 2025
Purchase(P)
Direct
1.6K shares at avg. $7.75$13K
TENX
TENAX THERAPEUTICS, INC.
May 16, 2025
Award(A)
Stock Option (right to buy)
Direct
1.4M shares-
TENX
TENAX THERAPEUTICS, INC.
Dec 10, 2024
Award(A)
Stock Option (right to buy)
Direct
1.3M shares-

		Type	Shares	Price		Ownership
Sep 15, 2026	TENX TENAX THERAPEUTICS, INC.	Purchase(P)	4,850	$1.82	$8,837	Direct
Sep 11, 2026	TENX TENAX THERAPEUTICS, INC.	Purchase(P)	6,000	$1.88	$11,250	Direct
Jul 13, 2026	TENX TENAX THERAPEUTICS, INC.	Exercise(M)	219	$3.55	$777	Direct
Jul 13, 2026	TENX TENAX THERAPEUTICS, INC.	Exercise(M)	8,500	$5.94	$50,490	Direct
Jan 9, 2026	TENX TENAX THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	450,000	-	-	Direct
Nov 20, 2025	TENX TENAX THERAPEUTICS, INC.	Purchase(P)	538	$7.59	$4,083	Direct
Nov 19, 2025	TENX TENAX THERAPEUTICS, INC.	Purchase(P)	455	$7.51	$3,417	Direct
Nov 18, 2025	TENX TENAX THERAPEUTICS, INC.	Purchase(P)	1,612	$7.75	$12,500	Direct
May 16, 2025	TENX TENAX THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	1,400,000	-	-	Direct
Dec 10, 2024	TENX TENAX THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	1,250,000	-	-	Direct

1-10 of 10 transactions

About Giordano Christopher Thomas

Giordano Christopher Thomas (SEC CIK 0001871714) files insider reports with the SEC as CEO of TENAX THERAPEUTICS, INC. (TENX).

Signal8 holds 6 ownership filings by Giordano Christopher Thomas, all Form 4s, filed between Dec 12, 2024 and Sep 15, 2026. Those filings report 10 transactions, from Dec 10, 2024 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Giordano Christopher Thomas's filings is in CHAPEL HILL, NC.

Recent filings by Giordano Christopher Thomas

Sep 15, 2026: Open-market purchase of TENX shares (Form 4, code P).
Sep 11, 2026: Open-market purchase of TENX shares (Form 4, code P).
Jul 13, 2026: Option exercises of TENX shares (2 lines, Form 4, code M).
Jan 9, 2026: Grant or award of TENX derivative securities (Form 4, code A).
Nov 20, 2025: Open-market purchase of TENX shares (Form 4, code P).

Other insiders filing for TENAX THERAPEUTICS, INC. (TENX)

ADAR1 Capital Management, LLC, 10% Owner
Doogan Declan, Director
STAAB THOMAS R II, Chief Financial Officer
MCGAULEY THOMAS, Interim CFO
Davidson Michael H., Director
Rich Stuart, Chief Medical Officer

How to read Form 4 transaction codes